300 related articles for article (PubMed ID: 26033088)
1. Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors.
Mingione A; Verdelli C; Terranegra A; Soldati L; Corbetta S
Curr Cancer Drug Targets; 2015; 15(7):563-74. PubMed ID: 26033088
[TBL] [Abstract][Full Text] [Related]
2. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.
Filopanti M; Verga U; Ermetici F; Olgiati L; Eller-Vainicher C; Corbetta S; Persani L; Beck-Peccoz P; Spada A
Eur J Endocrinol; 2012 Aug; 167(2):157-64. PubMed ID: 22577108
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet hydrochloride for the treatment of hyperparathyroidism.
Verheyen N; Pilz S; Eller K; Kienreich K; Fahrleitner-Pammer A; Pieske B; Ritz E; Tomaschitz A
Expert Opin Pharmacother; 2013 Apr; 14(6):793-806. PubMed ID: 23452174
[TBL] [Abstract][Full Text] [Related]
4. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels.
Kawata T; Imanishi Y; Kobayashi K; Onoda N; Okuno S; Takemoto Y; Komo T; Tahara H; Wada M; Nagano N; Ishimura E; Miki T; Ishikawa T; Inaba M; Nishizawa Y
J Bone Miner Metab; 2006; 24(4):300-6. PubMed ID: 16816924
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
7. Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?
Eidman KE; Wetmore JB
Semin Dial; 2018 Sep; 31(5):440-444. PubMed ID: 30009474
[TBL] [Abstract][Full Text] [Related]
8. Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis.
Moe SM; Wetherill L; Decker BS; Lai D; Abdalla S; Long J; Vatta M; Foroud TM; Chertow GM
Clin J Am Soc Nephrol; 2017 Jul; 12(7):1128-1138. PubMed ID: 28630081
[TBL] [Abstract][Full Text] [Related]
9. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.
Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A
Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106
[TBL] [Abstract][Full Text] [Related]
10. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
Fukagawa M; Shimazaki R; Akizawa T;
Kidney Int; 2018 Oct; 94(4):818-825. PubMed ID: 30049473
[TBL] [Abstract][Full Text] [Related]
11. Development of evocalcet for unmet needs among calcimimetic agents.
Hamano N; Endo Y; Kawata T; Fukagawa M
Expert Rev Endocrinol Metab; 2020 Sep; 15(5):299-310. PubMed ID: 32552012
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet: pharmacological and clinical aspects.
Messa P; Alfieri C; Brezzi B
Expert Opin Drug Metab Toxicol; 2008 Dec; 4(12):1551-60. PubMed ID: 19040330
[TBL] [Abstract][Full Text] [Related]
13. Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study.
Filipozzi P; Ayav C; Ngueyon Sime W; Laurain E; Kessler M; Brunaud L; Frimat L
BMJ Open; 2017 Mar; 7(3):e011482. PubMed ID: 28348181
[TBL] [Abstract][Full Text] [Related]
14. Reduction in parathyroid adenomas by cinacalcet therapy in patients with primary hyperparathyroidism.
Minezaki M; Takashi Y; Ochi K; Mitsuoka R; Yamao Y; Kudo T; Kawanami D; Kobayashi K; Abe I
J Bone Miner Metab; 2021 Jul; 39(4):583-588. PubMed ID: 33409573
[TBL] [Abstract][Full Text] [Related]
15. Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials.
Goodman WG
Pediatr Nephrol; 2003 Dec; 18(12):1206-10. PubMed ID: 14586685
[TBL] [Abstract][Full Text] [Related]
16. Calcium-sensing receptor activation in chronic kidney disease: effects beyond parathyroid hormone control.
Massy ZA; Hénaut L; Larsson TE; Vervloet MG
Semin Nephrol; 2014 Nov; 34(6):648-59. PubMed ID: 25498383
[TBL] [Abstract][Full Text] [Related]
17. Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.
Yamada S; Tokumoto M; Taniguchi M; Toyonaga J; Suehiro T; Eriguchi R; Fujimi S; Ooboshi H; Kitazono T; Tsuruya K
Ther Apher Dial; 2015 Aug; 19(4):367-77. PubMed ID: 25851690
[TBL] [Abstract][Full Text] [Related]
18. Activation of the calcium sensing receptor attenuates TRPV6-dependent intestinal calcium absorption.
Lee JJ; Liu X; O'Neill D; Beggs MR; Weissgerber P; Flockerzi V; Chen XZ; Dimke H; Alexander RT
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013259
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism.
Takeuchi Y; Takahashi S; Miura D; Katagiri M; Nakashima N; Ohishi H; Shimazaki R; Tominaga Y
J Bone Miner Metab; 2017 Nov; 35(6):616-622. PubMed ID: 27873072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
